Eledon Pharmaceuticals (ELDN) Operating Income (2013 - 2026)

Eledon Pharmaceuticals has reported Operating Income for 14 years, with the latest figure at -$21.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 17.91% year-over-year to -$21.2 million; the trailing twelve-month figure through Mar 2026 stood at -$82.9 million (down 468.02% YoY), and the FY2024 full-year result was -$7.5 million, up 69.32% from the prior year.
• Operating Income for Q1 2026 stood at -$21.2 million, down from -$19.1 million in the prior quarter.
• The five-year high for Operating Income was $38.4 million in Q4 2024, with the low at -$24.7 million in Q2 2025.
• Historically, Operating Income has averaged -$8.3 million across 5 years, with a median of -$11.0 million in 2023.
• The largest YoY upside for Operating Income was 368.59% in 2024 against a maximum downside of 83.16% in 2024.
• Eledon Pharmaceuticals' Operating Income stood at $11.3 million in 2022, then retreated by 27.32% to $8.2 million in 2023, then jumped by 368.59% to $38.4 million in 2024, then sank by 149.7% to -$19.1 million in 2025, then decreased by 11.07% to -$21.2 million in 2026.
• The last three Operating Income figures came in at -$21.2 million (Q1 2026), -$19.1 million (Q3 2025), and -$24.7 million (Q2 2025), per Business Quant data.